Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment
- PMID: 32600917
- DOI: 10.1016/j.gastrohep.2020.04.004
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment
Erratum in
-
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].Gastroenterol Hepatol. 2021 Apr;44(4):320. doi: 10.1016/j.gastrohep.2021.02.001. Epub 2021 Feb 25. Gastroenterol Hepatol. 2021. PMID: 33642094 English, Spanish. No abstract available.
Abstract
Pouchitis treatment is a complex entity that requires a close medical and surgical relationship. The elective treatment for acute pouchitis is antibiotics. After a first episode of pouchitis it is recommended prophylaxis therapy with a probiotic mix, nevertheless it is not clear the use of this formulation for preventing a first episode of pouchitis after surgery. First-line treatment for chronic pouchitis is an antibiotic combination. The next step in treatment should be oral budesonide. Selected cases of severe, chronic refractory pouchitis may benefit from biologic agents, and anti-TNF α should be recommended as the first option, leaving the new biologicals for multi-refractory patients. Permanent ileostomy may be an option in severe refractory cases to medical treatment.
Keywords: Colitis ulcerosa; Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Pouchitis; Reservoritis; Ulcerative colitis.
Copyright © 2020 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

